The Latest Breaking News from Schizophrenia

A growing body of research shows that bipolar disorder, schizophrenia and the in-between diagnosis of schizoaffective disorder share common genetic underpinnings

New research finds severe COVID increases the risk of schizophrenia — and could be a possible long COVID symptom

Paul Miller, who has paranoid schizophrenia, admitted a charge of attempted murder.

Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.

A request by an Adelaide prisoner with schizophrenia to move from a high-security jail to a mental health facility could have been a cry for help before he was released and killed an Adelaide mother, an inquest has heard.

Ian Fackender, who suffered from schizophrenia, had intense fears about emergency service sirens and was fatally shot by police in 2017. A coroner says there were many steps that could have been taken to reduce the risk to Mr Fackender and the officers.

Mental illness is a growing public health problem. In 2019, an estimated 1 in 8 people around the world were affected by mental disorders like depression, schizophrenia or bipolar disorder. While scientists have long known that many of these disorders run in families, their genetic basis isn’t entirely clear. One…

The actor is wowing audiences as Jonathan Blain, the son at the heart of Anne Deveson’s bestselling memoir Tell Me I’m Here. He talks about preparing for such a difficult role

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings growth prospects, the stock has gained more than 260% over the past month because the company submitted an NDA for…

Thomas Carl Hughes, who has paranoid schizophrenia, told officers that the explosives would be "activated" if they tried to force their way into his flat.

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…